hit counter
AtriCure, Inc. (ATRC) Stock News Sentiment & Price - Sentifly
ATRC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



AtriCure, Inc. (ATRC)

USA
Medical Instruments & Supplies
NASDAQ
ATRC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATRC Latest news
Seeking Alpha
Neutral
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2021 Results - Earnings Call Transcript
2021-11-03 19:08

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates
2021-11-03 19:07

AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
AtriCure Reports Third Quarter 2021 Financial Results
2021-11-03 16:01

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. “Our results were driven by strong growth across key product lines, including the addition of new Cryo Nerve Block and Hybrid AF™ Therapy accounts, providing further validation of demand across our business,” said Michael Carrel, President and Chief Executive Officer of Atri

Zacks Investment Research
Negative
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
2021-10-27 16:11

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
AtriCure to Participate in Upcoming Investor Conferences
2021-10-26 08:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2021 Virtual Healthcare Conference, on Wednesday, November 17, 2021. Management is scheduled to present at 8:40 a.m. Eastern Time. Interested parties may access a live audio webcast of

Business Wire
Neutral
AtriCure to Announce Third Quarter 2021 Financial Results
2021-10-05 08:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, November 3, 2021 to discuss its third quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for d

Business Wire
Neutral
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-31 08:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference. AtriCure's management is scheduled to present on Tuesday, September 14, 2021, at 11:45 a.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by

Seeking Alpha
Neutral
AtriCure's (ATRC) CEO Mike Carrel on Q2 2021 Results - Earnings Call Transcript
2021-08-07 17:38

AtriCure's (ATRC) CEO Mike Carrel on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
2021-08-04 19:04

AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
AtriCure Reports Second Quarter 2021 Financial Results
2021-08-04 16:01

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward making our platforms the standard of care,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We a

Loading more news...